

## Seeking Redevelopment Opportunities for the Treatment of Rare or Orphan Diseases

Healx, an AI-powered, patient-inspired, biotech company based in Cambridge (UK), is seeking drug redevelopment opportunities from academics, clinicians or recent university spinouts in the area of **Rare Disease**. Healx will collaborate with the asset holders to quickly turn their research into approved treatments that benefit the rare disease community.



### Approaches of Interest

- Open to **rare or orphan diseases (prevalence <5/10,000) with current unmet medical needs**, with a particular interest in rare **renal, inflammatory, neuromuscular, bone and ocular conditions**
- Ideally, the rare or orphan indication has well-characterised natural history, established clinical trial endpoints and/or biomarkers and, if applicable, sufficient patients willing and able to participate in clinical trials
- Healx is open to most modalities, with a particular interest in small molecules, as well as new platform technologies (e.g. novel delivery systems) that are (nearly) market-ready and can improve patient outcomes and create commercially viable drug redevelopment

### Stage of Development

- Healx is open to opportunities at the basic to clinical stage, mostly favouring the late preclinical and clinical stages
- Preclinically-validated in models (*in vitro* and/or *in vivo*) that are representative of the disease of interest are preferred

### Ideal Candidate Profile

- Drug redevelopment (modifying an approved drug, nutraceutical or human-safe compound for the treatment of a new indication) or late-stage new chemical entity (NCE) candidates, or new technology platforms to aid drug redevelopment
- Patent protection available or already prosecuted (composition of matter, method of use and/or formulation patents)
- For opportunities redeveloping approved drugs or nutraceuticals: there needs to be a chance to create or enhance both patient impact and commercial viability through reformulation, combination or other modifications






### Out of Scope

- Gene therapy, biologics and cell therapy approaches are not of interest
- For rare oncology, Healx is not currently looking for opportunities in acute metastatic cancers with multiple genetic origins but they are open to opportunities related to single gene-derived benign tumour types, e.g. neurofibromatosis

### Opportunity for Collaboration and Submission Information

- Healx is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include in-licensing clinic-ready assets for clinical development, option agreements with research funding and co-development for preclinical assets
- Submission of one page, 200-300 word briefs or completion of the **optional submission form** are encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information

### Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

### Submissions

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](https://discover.in-part.com)

Deadline: **23rd August 2021 - 10:59 pm GMT**

#### Have any questions?

Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

